



ASGCT 27th Annual Meeting Recap

May 7 - 11, 2024 - Baltimore, MD



ATTENDANCE


2024: 7,800+ total attendees
(91% in-person, 9% virtually)



2023: 7,900+ attendees (86% in-person, 14% virtually)

2022: 7,600+ attendees (in-person & virtual)

INTERNATIONAL PRESENCE:
(46 countries represented)



45% Decision Maker for Organization

48% 10+ Years Professionals

ORGANIZATION TYPE

- 67% Industry/Corporate
- 20% Academic
- 4% Non-profit
- 4% Government/Regulatory Agency



Top Industry Areas:
#1: Biotechnology
#2: Pharmaceutical/
Clinical Stage
Therapy

PRIMARY ROLES

- 45% Researcher/Scientist
- 16% Executive/Organization Leader
- 10% Business Development
- 8% Marketing/Sales
- 6% Other Corporate/Commercial
- 4% Student
- 3% Physician
- 2% Regulatory Affairs Professional
- 2% Financial Investment
- 1% Non-Profit
- 1% Patient Advocate
- 1% Gov. Relation/Market Access Professional
- 1% Other Healthcare Provider

EDUCATIONAL IMPACT AND PARTICIPATION

- 260 Speakers
- 451 Abstract Oral Presentations
- 1,473 Abstract Posters
- 30 Sponsored Symposia
- 35 Tools & Technology Forum
- 110 Sponsors
- 339 Exhibitors

25,000+ Exhibitor Leads Captured



250+ Hours of programming!

SOCIAL MEDIA AND PRESS

65 Media Registrants

42 Media Outlets

20% Increase in media presence from 2023

Featured Articles

[ASGCT: Ring's 'new class of viral vector' is re-dosable in primates, overcoming key challenge of AAVs](#)

[ASGCT2024: FDA's Marks on Accelerated Approval, Gene Therapy Costs and More](#)

[At ASGCT, Regeneron Presents Update on Gene Therapy for Genetic Deafness](#)

annualmeeting.asgct.org